Testosterone is increasingly considered in the management of low libido and sexual wellbeing in midlife women, yet its use in breast cancer survivors remains an area of uncertainty and clinical debate.

In this session, Dr. Sarah Glynne will examine the current evidence surrounding testosterone therapy in women with a history of breast cancer, including safety data, physiologic dosing principles, and areas where research remains limited. Drawing on a menopause specialist's perspective, she will explore how to approach complex risk discussions, support shared decision-making, and individualize care for women seeking symptom relief while prioritizing long-term health and oncologic safety.

This session will provide clinicians with a balanced, practical framework for navigating one of the most nuanced topics in menopause care today.

Sarah Glynne, MBChB, MRCOG, is a UK-based Consultant Gynaecologist and Menopause Specialist with expertise in managing complex menopause care, including in women with a history of breast cancer. She works in both NHS and private practice settings and is recognized for her evidence-based, individualized approach to decision-making in hormone therapy. Dr. Glynne has a particular interest in balancing symptom management, sexual health, and quality of life with oncologic safety, helping women navigate nuanced hormonal treatment choices with clarity and confidence.